Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi ruxolitinib compared to anagrelide for the treatment of patients with essential thrombocythemia ET who are resistant to or intolerant of hydr [...]

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

1 Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians Pick your primary hematologistoncologist carefully rely on people you [...]

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma CTCL- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- Cutaneous T-cell lymphoma is a blood cancer of [...]

Kisqali® Improves Outcomes for Premenopausal Women with HR+/HER2- Advanced Breast Cancer

Premenopausal breast cancer is a biologically distinct and more aggressive disease than postmenopausal breast cancer and is the leading cause of cancer death in women 20-59 years old12 3 Historically there younger women were treated the same as their olde [...]

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

The Food and Drug Administration granted regular approval to Alcensa alectinib for treatment of patients with anaplastic lymphoma kinase ALK-positive metastatic non-small cell lung cancer NSCLC as detected by an FDA-approved test In December 2015 Alcensa [...]

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

Opdivo nivolumab a novel checkpoint inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma RCC1 Treatment options for RCC continue to expand and are [...]

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

The US Food and Drug Administration has granted accelerated approval to Calquence acalabrutinib for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy Mantle cell lymphoma is a particularly aggressive cancer and [...]

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy ExteNET trial were presented at the European Society of Medical Oncology ESMO [...]

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio abemaciclib a cyclin-dependent kinase CDK 4 38 6 inhibitor when administered in combination with fulvestrant significantly improves the time to cancer progressi [...]

Radius Health Receives FDA Fast Track Designation for Elacestrant

The US Food and Drug Administration FDA has granted Fast Track designation for elacestrant an investigational oral selective estrogen receptor down-regulatordegrader SERD as a treatment of women with ER and HER2- advanced or metastatic breast cancer Fast [...]